Pletz Mathias W, Welte Tobias, Ott Sebastian R
F1000 Med Rep. 2010 Jul 22;2:53. doi: 10.3410/M2-53.
Despite the availability of powerful antibiotics, community-acquired pneumonia (CAP) remains one of the leading reasons for morbidity and mortality worldwide, and despite the availability of powerful antibiotics, there has been only little improvement in case fatality rates for many years. Consequently, it cannot be expected that novel antibiotics will substantially improve outcomes in CAP. Therefore, this review focuses on novel approaches that may reduce CAP-related mortality: the impact of immunomodulation by macrolides and fluoroquinolones and the prevention of CAP by pneumococcal vaccines.
尽管有强效抗生素，但社区获得性肺炎（CAP）仍是全球发病和死亡的主要原因之一，而且尽管有强效抗生素，多年来病死率几乎没有改善。因此，不能期望新型抗生素能显著改善CAP的治疗结果。因此，本综述重点关注可能降低CAP相关死亡率的新方法：大环内酯类和氟喹诺酮类药物的免疫调节作用以及肺炎球菌疫苗预防CAP的作用。
